Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v2.4.0.8
Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
12 Months Ended 90 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2013
Operating expenses:        
Research and development $ 25,682 $ 17,468 $ 8,583 $ 67,691
General and administrative 10,098 8,665 5,755 26,377
In-process research and development 0 1,043 20,706 21,749
Loss from operations (35,780) (27,176) (35,044) (115,817)
Interest income 545 236 165 1,025
Interest expense (1,923) (670) (74) (5,876)
Other income 0 0 0 733
Warrant expense 0 0 (1,407) (1,407)
Net loss (37,158) (27,610) (36,360) (121,342)
Common Stock dividend to Series A Convertible Preferred Stockholders 0 0 (5,861) (5,861)
Net loss attributed to Common stockholders $ (37,158) $ (27,610) $ (42,221) $ (127,203)
Basic and diluted net loss per common share $ (1.22) $ (1.27) $ (5.51)  
Weighted average common shares outstanding—basic and diluted 30,429,743 21,654,984 7,662,984